当前位置: 首页 > 期刊 > 《新医学》 > 201811
编号:13571920
焦磷酸钙盐沉积症腰椎病变11例临床分析(3)
http://www.100md.com 2018年11月1日 《新医学》 201811
     [3] Brandt KD, Schumacher HR. Osteoarthritis and crystal deposition diseases. Curr Opin Rheumatol,1996,8:235?237.

    [4] Sekijima Y, Yoshida T, Ikeda S. CPPD crystal deposition disease of the cervical spine: a common cause of acute neck pain encountered in the neurology department. J Neurol Sci, 2010,296(1?2):79?82.

    [5] Rosales?Alexander JL, Balsalobre Aznar J, Magro?Checa C. Calcium pyrophosphate crystal deposition disease: diagnosis and treatment. Open Access Rheumatol, 2014,6:39?47.
, 百拇医药
    [6] 房惠琼,李启明,黄耀渠,邢基斯, 毛荣军 ,谢乐. 焦磷酸钙结晶沉积症20例的臨床病理分析. 中华病理学杂志, 2012,41(12): 828?832.

    [7] Ryu K, Iriuchishima T, Oshida M. Kato Y, Saito A, Imada M, Aizawa S, Tokuhashi Y, Ryu J. The prevalence of and factors related to calcium pyrophosphate dihydrate crystal deposition in the knee joint. Osteoarthritis Cartilage, 2014,22(7):975?979.

    [8] Scutellari PN, Galeotti R, Leprotti S, Ridolfi M, Franciosi R, Antinolfi G. The crowned dens syndrome. Evaluation with CT imaging. Radiol Med, 2007,112(2):195?207.
, 百拇医药
    [9] Sekijima Y, Yoshida T, Ikeda S. CPPD crystal deposition disease of the cervical spine: a common cause of acute neck pain encountered in the neurology department. J Neurol Sci, 2010, 296(1?2):79?82.

    [10] Wu Y, Chen K, Terkeltaub R. Systematic review and quality analysis of emerging diagnostic measures for calcium pyrophosphate crystal deposition disease. RMD Open, 2016, 2(2):e000339.

    [11] Wendling D, Prati C, Hoen B, Godard J, Vidon C, Godfrin?Valnet M, Guillot X. When gout involves the spine: five patients including two inaugural cases. Joint Bone Spine,2013,80(6):656?659.
, 百拇医药
    [12] 黄叶飞,谢雅,古洁若.脊柱痛风石一例. 新医学,2017,48(6):428?432.

    [13] Firestein GS,Budd RC,Gabriel SE. Kelley & Firesteins textbook of rheumatology. 10th ed . Philadelphia, PA: Elsevier, 2017:1754.

    [14] Kobayashi S, Pappas E, Fransen M, Refshauge K, Simic M. The prevalence of patellofemoral osteoarthritis: a systematic review and meta?analysis. Osteoarthritis Cartilage,2016,24(10):1697?1707.

    [15] Rothschild B, Yakubov LE. Prospective 6?month, double?blind trial of hydroxychloroquine treatment of CPDD. Compr Ther,1997,23(5): 327?331.
, 百拇医药
    [16] Andres M, Sivera F, Pascual E. Methotrexate is an option for patients with refractory calcium pyrophosphate crystal arthritis. J Clin Rheumatol,2012,18(5):234?236.

    [17] Cheung HS. Phosphocitrate as a potential therapeutic strategy for crystal deposition disease. Curr Rheumatol Rep,2001,3(1):24?28.

    (收稿日期:2018?08?03)

    (本文编辑:洪悦民), http://www.100md.com(郭奇虹 郑宝林 霍智铭 李婷 杨剑 陈君立)
上一页1 2 3